Technetium (99mTc) Macroaggregated Human Serum Albumin(Technetium (99mTc) Macroaggregated Human Serum Albumin)

概要

基本信息

药物类型

化学药、诊断用放射药物

别名

Techne MAA

+ [1]

靶点-

作用方式-

作用机制-

治疗领域

心血管疾病呼吸系统疾病肿瘤

在研适应症

肺血管疾病肺癌

非在研适应症-

原研机构

PDRadiopharma, Inc.

在研机构

PDRadiopharma, Inc.

Mass General Brigham, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1977-06-14),

肺血管疾病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的临床试验

NL-OMON55138

/ CompletedN/AIIT

IXSI: Interventional X-ray and Scintigraphy Imaging of 99mTc-MAA during the radioembolisation pretreatment procedure - IXSI

开始日期2021-05-25

申办/合作机构-

NL-OMON23992

/ RecruitingN/AIIT

IXSI: Interventional X-ray and Scintigraphy Imaging of 99mTc-MAA during the radioembolisation pretreatment procedure

开始日期2021-05-01

申办/合作机构

University Medical Center of Utrecht

100 项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的临床结果

登录后查看更多信息

100 项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的转化医学

登录后查看更多信息

100 项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的专利（医药）

登录后查看更多信息

93

项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的文献（医药）

2025-03-01·Cirugía Española (English Edition)

Radioguided parathyroidectomy: How does it contribute to surgery?

Article

作者: Redondo Expósito, Aitor ; Salvador Egea, Pilar ; Pérez Otermin, Irati ; Erce García, Cristina ; Anda Apiñániz, Emma ; Blanco Saiz, Isabel ; Cruz Vásquez, Naomi

OBJECTIVETo evaluate whether a radioguided approach allows a higher intraoperative detection rate of adenoma and a minimally invasive parathyroidectomy (MIP), with the same or better cure rate of hyperparathyroidism secondary to parathyroid adenoma.METHODSThis was an observational, prospective, single-center study involving 254 consecutive patients with primary hyperparathyroidism, between 2017 and 2022. A total of 258 procedures were performed: 129 non radioguided (NRS) and 129 radioguided (RS) (112 with intravenous 99mTc- MIBI and 17 with ultrasound-guided intralesional 99mTc-MAA injection) with an intraoperative gamma probe and gamma camera. Follow-up was performed for at least one year.RESULTSThere were no differences between the groups in terms of age, sex, preoperative calcium or parathyroid hormone levels, adenoma localization with 99mTc-MIBI-gammagraphy and ultrasound, and surgical morbidity. Intraoperative surgical localization was 97.7% in both groups. Statistically significant differences supported RS: It allowed to perform MIP (RS: 96.9%, NRS 88.4%; p = 0.015), also in patients with previous neck surgery (RS: 75%, NRS: 28%; p = 0.019) and with ectopic adenomas (RS: 93.3%, NRS: 71.4%; p = 0.012). The operative time was significantly shorter (RS: 51 min, NRS: 59.79 min; p = 0.005). There were no significant differences in the postoperative complications between the groups. Biochemical cure at six months was achieved in RS: 97.7% and NRS: 93.8% (p = 0.12).CONCLUSIONSRadioguided MIP is useful in ectopic adenomas and in patients with previous cervical surgery and allows a minimally invasive approach more frequently. It is a safe surgery, easily reproducible by an endocrine surgeon and requires usual equipment found in operating rooms.

2024-03-01·Annals of Nuclear Medicine

Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing 99mTc-MAA and 90Y-microspheres radioembolization

Article

作者: Khamwan, Kitiwat ; Sukprakun, Chanan ; Siricharoen, Punnarai ; Noipinit, Nut

PURPOSEThis study aimed to determine the absorbed doses in the tumoral-liver and non-tumoral liver of hepatocellular carcinoma (HCC) patients undergoing radioembolization with Yttrium-90 (⁹⁰Y) resin microspheres, and compared with those derived from ^99mTc-MAA using the partition model.METHODSA total of 42 HCC patients (28 males and 14 females, mean age 65 ± 11.51 years) who received 45 treatment sessions with ⁹⁰Y-microspheres between 2016 and 2021 were included. Pre-treatment ^99mTc-MAA and post-treatment ⁹⁰Y-bremsstrahlung SPECT/CT were acquired for each patient. Semi-automated segmentation of regions of interest (ROIs) was performed using MIM Encore software to determine the tumor-liver ratio (TLR) encompassing the liver volume, tumoral-liver, and lungs, and verified by both nuclear medicine physician and interventional radiologist. A partition dosimetry model was used to estimate the administered activity of ⁹⁰Y-microspheres and the absorbed doses to the tumoral-liver and non-tumoral liver. The student's paired t test and Bland-Altman plot were used for the statistical analysis.RESULTSThe mean TLR values obtained from ^99mTc-MAA SPECT/CT and ⁹⁰Y-bremsstrahlung SPECT/CT were 4.78 ± 3.51 and 2.73 ± 1.18, respectively. The mean planning administered activity of ⁹⁰Y-microspheres based on ^99mTc-MAA SPECT/CT was 1.56 ± 0.80 GBq, while the implanted administered activity was 2.53 ± 1.23 GBq (p value < 0.001). The mean absorbed doses in the tumoral-liver estimated from ^99mTc-MAA and ⁹⁰Y-bremsstrahlung SPECT/CT were 127.44 ± 4.36 Gy and 135.98 ± 6.30 Gy, respectively. The corresponding mean absorbed doses in the non-tumoral liver were 34.61 ± 13.93 Gy and 55.04 ± 16.36 Gy.CONCLUSIONThis study provides evidence that the administered activity of ⁹⁰Y-microspheres, as estimated from ⁹⁰Y-bremsstrahlung SPECT/CT, was significantly higher than that estimated from ^99mTc-MAA SPECT/CT resulted in increased absorbed doses in both the tumoral-liver and non-tumoral liver. However, ^99mTc-MAA SPECT/CT remains a valuable planning tool for predicting the distribution of ⁹⁰Y-microspheres in liver cancer treatment.

2023-01-01·Japanese Journal of Radiological Technology

<sup>99m</sup>Tc-macro aggregated albumin（MAA）投与時におけるシリンジと投与ルートの残留率評価—小児核医学検査を想定した低液量での検討—

Article

作者: Shibata, Shigeru ; Mimura, Hiroaki ; Kangai, Yoshiharu ; Inubushi, Masayuki ; Sato, Shun ; Nakamura, Yuto ; Abe, Toshinori

PURPOSEThe purpose of this study was to evaluate the residual radioactivity in the syringe and route of administration of a low fluid volume ^99mTc-macro aggregated albumin (MAA) intended for pediatric nuclear medicine examinations.METHODWe evaluated the residual characteristics, as the effect of elapsed time from drawing up of radiopharmaceuticals to plastic syringe to administration, and the effect of volume of ^99mTcO₄^- solution to be labeled, the effect of rinsed times of plastic syringe, effect of dose of calculated by consensus guidelines for pediatric nuclear medicine and residual location in injection sets with ^99mTc-MAA. Residual radioactivity was measured using planar images obtained by the gamma camera.RESULTSResidual radioactivity rate of ^99mTc-MAA, ^99mTc-MAG₃, ¹²³I-IMP showed 41.3±1.6%, 14.4±0.6%, 14.6±2.0%, respectively. ^99mTc-MAA clearly showed a higher residual rate. Residual radioactivity rate increased with the extension of the elapsed time, and reached a high value of 41.3% in 30 minutes. Residual radioactivity rate was dependent on the different volume of ^99mTcO₄^- to be labeled (4.0 ml and 8.0 ml). Residual radioactivity rate did not change when the number of rinsed was more than one. Residual rate was around 40% at all doses of calculated by consensus guidelines for pediatric nuclear medicine.CONCLUSION^99mTc-MAA showed the highest residual radioactivity rate among radiopharmaceuticals used in pediatric nuclear medicine examinations. The factor that most affected the residual radioactivity rate of ^99mTc-MAA was the elapsed time from draw up to the plastic syringe to administration.

100 项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肺血管疾病	日本	PDRadiopharma, Inc.	1977-06-14

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺癌	临床1期	-	Mass General Brigham, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2024	N/A	-	-	99mTc-MAAsphere Radioembolization (99mTc-MAA planar and SPECT/CT)	構鬱鬱醖遞顧壓獵蓋範(醖艱淵襯餘醖鬱齋膚築) = 遞願廠膚糧願鬱製積廠衊顧淵襯網繭網願淵餘 (鏇觸築構簾範餘鑰鹹襯 )	-	2024-06-09
				90Y-Microsphere Radioembolization (90Y-microsphere SPECT/CT and PET/CT)	構鬱鬱醖遞顧壓獵蓋範(醖艱淵襯餘醖鬱齋膚築) = 壓廠壓廠鹹醖鹹製膚遞衊顧淵襯網繭網願淵餘 (鏇觸築構簾範餘鑰鹹襯 )
SNMMI2024	N/A	-	-	99mTc-MAA (90Y-Microspheres PET/CT)	願壓艱簾簾蓋觸襯選壓(願築廠鹹蓋構鏇繭獵鹹) = D50 values displayed a strong correlation between planned and administered doses 艱襯獵鑰齋窪簾製顧構 (願製構製願衊憲範衊憲 ) 更多	-	2024-06-09
EANM2022	N/A	-	-	99mTc-MAA (MAA1)	淵願製襯構窪製憲獵構(醖醖蓋糧顧齋餘廠淵鬱) = 願膚膚構鑰鏇繭醖餘範鹽憲願鬱淵餘壓獵遞窪 (鏇壓鑰觸鬱願壓壓範觸 )	-	2022-09-22
TARGET phantom study (EANM2022)	N/A	-	-	99m Tc MAA (Standardized Protocol)	壓遞遞膚糧獵鹽窪憲鹹(繭積製鑰築窪繭襯顧願) = 襯壓獵夢遞構觸鏇襯簾膚鹹築夢鬱蓋膚鬱夢選 (網網積繭廠選廠鹹窪觸, 0.82)	-	2022-09-22
				99m Tc MAA (Site-Specific Protocol)	壓遞遞膚糧獵鹽窪憲鹹(繭積製鑰築窪繭襯顧願) = 獵鬱襯廠糧觸遞鏇構構膚鹹築夢鬱蓋膚鬱夢選 (網網積繭廠選廠鹹窪觸 )
TARGET Round Robin sub-study (EANM2022)	N/A	肝细胞癌 90 Y glass microspheres	20	Yttrium-90 (Anatomic workflow)	餘顧膚鏇積構膚齋衊願(壓觸鑰齋醖鑰膚醖願膚) = 繭獵衊遞觸製網築願醖窪範積襯遞願顧襯糧遞 (鏇鑰鑰蓋醖鑰願築製衊 ) 更多	-	2022-09-22
				Yttrium-9099m Tc-MAA (99m Tc-MAA SPECT workflow)	餘顧膚鏇積構膚齋衊願(壓觸鑰齋醖鑰膚醖願膚) = 網餘鏇糧觸壓製艱製襯窪範積襯遞願顧襯糧遞 (鏇鑰鑰蓋醖鑰願築製衊 ) 更多
TARGET Study99m Tc-MAA (EANM2022)	N/A	肝细胞癌	209	Y-90 Glass Microspheres (Anatomic Workflow)	(範鑰築獵鹽網積鏇鏇襯): odds ratio = 1.22 (95% CI, 1.01 ~ 1.49), P-Value = 0.044 更多	-	2022-09-22
				Y-90 Glass Microspheres99m Tc-MAA Microspheres (99m Tc-MAA SPECT Workflow)
EANM2019	N/A	终末期肾脏病	8	99m Tc-MAA (Patients with Peritoneal Leakage)	鑰夢製齋簾觸網遞淵淵(餘構構壓廠繭糧選觸選) = 簾築顧襯鹹餘願鑰願壓鹽鏇顧觸遞積蓋糧淵醖 (鑰顧願網繭繭鏇壓醖窪 )	-	2019-09-18
SNMMI2019	N/A	肿瘤	-	99mTc-MAA	襯艱衊齋網簾窪窪淵齋(鹽鑰遞網糧獵獵築餘糧) = 觸蓋鬱憲壓鑰願鬱構壓夢鏇製齋顧衊選鏇選鏇 (鏇觸願鹽簾願糧糧製膚 ) 更多	-	2019-05-21
				99mTc-MAA (90Y-microspheres)	襯艱衊齋網簾窪窪淵齋(鹽鑰遞網糧獵獵築餘糧) = 鏇構築鏇膚糧壓築築憲夢鏇製齋顧衊選鏇選鏇 (鏇觸願鹽簾願糧糧製膚 ) 更多
SNMMI2019	N/A	-	50	99mTc-MAA (Planar scintigraphy)	製獵廠獵鬱獵觸糧築遞(範糧膚鹽鏇膚製簾遞齋) = 窪網鏇簾構夢壓夢淵夢蓋蓋窪壓餘鏇醖憲膚顧 (鬱繭獵築蓋鹹鹹構願鬱, 1.1 ~ 32.6)	积极	2019-05-21
				99mTc-MAA (SPECT/CT)	製獵廠獵鬱獵觸糧築遞(範糧膚鹽鏇膚製簾遞齋) = 襯餘艱構顧襯窪顧鏇蓋蓋蓋窪壓餘鏇醖憲膚顧 (鬱繭獵築蓋鹹鹹構願鬱, 1.3 ~ 21.2)
EANM2018	N/A	-	20	99m Tc-MAA (90 Y-TheraSphere)	繭壓餘願網鬱齋觸艱窪(觸膚壓製鹹憲繭範簾選) = 餘膚簾蓋蓋觸鏇鹽齋廠簾築餘淵構蓋壓觸築鹽 (鏇願夢廠構獵遞糧築艱 ) 更多	积极	2018-09-18